Document Detail

Friend or foe: the role of microRNA in chemotherapy resistance.
Jump to Full Text
MedLine Citation:
PMID:  23624759     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Chemotherapy has been widely used in treating cancer patients. Despite the tremendous progress in cancer treatment achieved during the last decades, drug resistance still accounts for most of the tumor relapses in chemotherapy-treated patients. Emerging evidence shows that microRNAs play an important role in regulating the drug sensitivity of tumor cells. However, the mechanism of microRNA-mediated drug resistance is not fully understood. Current data suggest that microRNAs can be categorized as oncogenic or tumor-suppressive based on their functions and targets. In tumor cells undergoing drug treatment, microRNAs can function either by decreasing expression of genes associated with multiple drug resistance or by promoting escape from apoptosis and inducing tumor stem cell development. This review aims to provide an updated understanding of the role of microRNAs in regulating chemotherapy resistance and a discussion of potential therapeutic applications.
Authors:
Haoran Li; Burton B Yang
Related Documents :
24069069 - The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemci...
25052479 - Monitoring reversal of met-mediated resistance to egfr tyrosine kinase inhibitors in no...
23664449 - Favorable prognosis of operable non-small cell lung cancer (nsclc) patients harboring a...
23912459 - Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of ...
21931769 - Suppression of breast tumor growth and metastasis by an engineered transcription factor.
24568699 - Science to practice: why debate the role of dbait for improving tumor ablation?
8889509 - Detailed deletion analysis of sporadic breast tumors defines an interstitial region of ...
7933249 - The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine...
2197839 - Myeloma with involvement of the serous cavities. cytologic and immunochemical diagnosis...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-4-29
Journal Detail:
Title:  Acta pharmacologica Sinica     Volume:  -     ISSN:  1745-7254     ISO Abbreviation:  Acta Pharmacol. Sin.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-4-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100956087     Medline TA:  Acta Pharmacol Sin     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1] Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto [2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Acta Pharmacol Sin
Journal ID (iso-abbrev): Acta Pharmacol. Sin
ISSN: 1671-4083
ISSN: 1745-7254
Publisher: Nature Publishing Group
Article Information
Download PDF
Copyright © 2013 CPS and SIMM
open-access:
Received Day: 25 Month: 02 Year: 2013
Accepted Day: 12 Month: 03 Year: 2013
Print publication date: Day: 05 Month: 07 Year: 2013
Electronic publication date: Day: 29 Month: 04 Year: 2013
Volume: 34 Issue: 7
First Page: 870 Last Page: 879
PubMed Id: 23624759
ID: 3703710
Publisher Item Identifier: aps201335
DOI: 10.1038/aps.2013.35

Friend or foe: the role of microRNA in chemotherapy resistance
Haoran Li12
Burton B Yang12*
1Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto
2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
*E-mail byang@sri.utoronto.ca

Introduction

Chemotherapy, together with surgery and radiotherapy, has been a main approach for cancer treatment. Most chemotherapeutic agents function by interfering with DNA replication and cell mitosis, inhibiting protein synthesis and inducing cell damage. Chemotherapy is often effective in diminishing rapid tumor cell growth as well as minimizing metastatic disease. In recent decades, tremendous efforts have been made to improve the efficacy of anticancer agents. For malignancies such as lymphoma, leukemia and small cell lung cancer, chemotherapy has been used as first-line therapy. As an adjuvant therapy, chemotherapy is widely used to prevent tumor recurrence by eliminating residual lesions. When used alone or combined with radiotherapy, neoadjuvant chemotherapy can even reduce tumor size before surgery, curing otherwise incurable patients. However, the development of drug resistance often results in the failure of chemotherapy, especially in advanced cancer patients. In general, there are two classes of drug resistance: inherent (natural) resistance and acquired resistance. Inherent resistance can be partially overcome by incorporating multiple agents into chemotherapy regimens, while acquired resistance to chemotherapeutic drugs accounts for greater than 90% of unsuccessful treatments in advanced cancer patients1. As a result of drug resistance, tumors often relapse more aggressively and metastasize to distant organs, leading to devastating outcomes. The mechanisms of chemotherapeutic drug resistance still remain largely unknown despite extensive investigation. The response of cancer cells to treatment indicates that chemotherapy resistance could be due to either genetic or epigenetic factors, including (1) overexpression of drug resistance-related proteins, (2) altered drug targets, (3) decreases in drug concentrations, and (4) escape from cell cycle checkpoints. Emerging evidence indicates that tumor angiogenesis and stem cell development are also responsible for chemoresistance.

It is known that cancer consists of a group of genetically heterogenetic cells. Chemotherapeutic drug treatment transforms predominant, fast-dividing cells into drug-resistant ones. These cells are thought to be the cause of subsequent tumor recurrence. During transformation, tumor cells undergo dramatic changes at the genetic and epigenetic level. MicroRNAs (miRNAs) have evolved as a major force in regulating gene expression and the phenotype of tumor cells because of their diverse functions in cell proliferation2,3,4, cell cycle progression5,6,7, survival8,9, invasion10,11,12, cell differentiation13,14, and morphogenesis15. The activities of miRNAs are also regulated by non-coding RNAs. This was initially demonstrated by us using the 3′UTR of versican, which induces organ adhesion by modulating miRNA function16,17. Further studies indicated that a number of 3′UTRs possess the ability to regulate miRNA function18,19,20. In addition, pseudogenes and long non-coding RNAs can modulate miRNA function21,22. This complicated network makes it difficult to understand the intrinsic mechanisms. Hence, there is a pressing need to decipher the molecular mechanism of miRNA-regulated drug resistance and its therapeutic implications. In this review, the role of microRNAs in anticancer drug resistance will be explored in light of current knowledge.


MicroRNA as a key regulator in cancer

MicroRNAs are non-coding RNAs of 20–22 bases in length that are broadly conserved across species. MiRNAs do not encode any proteins but regulate gene expression post-transcriptionally. Most miRNA loci are found in non-coding intronic transcription regions, but some are located in exonic regions23. MiRNA genes are transcribed by RNA polymerase II (pol II) to primary miRNAs (pri-miRNAs), which are then processed by the Drosha-DGCR8 complex to release hairpin intermediate precursor miRNAs (pre-miRNAs). Pre-miRNA hairpins bind to exportin-5 and are exported to the cytoplasm where pre-miRNAs are cleaved by the RNase III-type enzyme Dicer. Normally, two miRNA strands, named miRNA-3p and miRNA-5p, are produced from opposite arms of one pre-miRNA23. Previously it was thought that one strand is a mature miRNA and the other strand (the passenger strand) is degraded, but the current theory is that both arms can be selected as a mature miRNA in a tissue-specific context24. Mature miRNAs are incorporated into the RNA-induced silencing complex (RISC) to cleave target mRNA or repress mRNA translation by binding to its 3′-untranslated region (3′-UTR). However, some studies have shown that miRNAs can activate mRNA translation by binding to the 5'-UTR of their targets25. More recently, some miRNAs have been found to bind to decoy mRNAs in a RISC-independent way26 (Figure 1).

To date, research has demonstrated that miRNAs are linked to approximately 300 human diseases, especially cancer27,28,29,30. MiRNAs are broadly involved in cancer development, metastasis, angiogenesis and drug resistance. Because miRNAs are differentially expressed in human cancers, they can be categorized as oncogenic or tumor-suppressive according to their influence on cancer cell growth31,32,33,34. Oncogenic miRNAs (oncomirs) induce cancer cell proliferation by down-regulating expression of tumor suppressor genes, whereas tumor suppressor miRNAs (mirsupps) inhibit cancer progression by targeting oncogenes post-transcriptionally (Figure 2). These miRNAs can be distinguished based on chromosome distribution, evolutionary rate and function. Oncomirs tend to be amplified in human cancers, whereas mirsupps are frequently cleaved35. However, this dichotomous approach has its limitations. On one hand, it is important to note that miRNAs may act in a tissue-specific way such that a single miRNA type can be either an oncomir or a mirsupp in different types of tumors. For example, miRNA-17 was found to accelerate tumor development in B-cell lymphoma, while it can suppress breast cancer growth by down-regulating AIB1 expression36,37. On the other hand, these and similar studies were based on experiments conducted in vitro where the body's immunity response and the tumor microenvironment are overlooked. Emerging models have shown that some miRNAs sensitize tumors to treatment while promoting tumor growth in vitro and that these miRNAs could even be used as predictive markers for clinical outcome38. As indicated above, we exploited miR-17's function in glioblastoma cells. We found that miR-17 targets the oncogene MDM2 and the tumor suppressor gene PTEN simultaneously, resulting in retardation of cell growth but prolonged cell survival39. Interestingly, the detected chemoresistance was partly a result of tumor stem cell generation39. MiR-17 also targets vimentin and GalNT7 and induces development of hepatocellular carcinoma40. Clearly, the biological effects of miRNAs in cancer are more complex than was once recognized (Figure 2).


MicroRNAs regulate drug resistance-related proteins

The term multiple drug resistance (MDR) refers to the condition when resistance to one drug is followed by resistance to multiple, often completely different, other drugs. Most known MDR proteins belong to the ATP-binding cassette (ABC) family, which includes P-glycoprotein (P-gp/MDR-1/ABCB1/CD243), MDR-associated protein (MRP1/ABCC1) and breast cancer-resistant protein (BCRP/ABCG2). These proteins have similar trans-membrane domains and protect tumor cells from the influx of harmful drugs by pumping the drugs out41. To mimic the chemoresistant phenotype in vitro and study MDR mechanisms, drug-resistant cancer cell lines have been developed. Despite the change in protein levels, microarray analysis has disclosed transitions in miRNA expression. Some miRNAs, such as miR-19, miR-21, and miR-34a42,43,44, are elevated several fold in chemoresistance cell lines and are thought to play a role in cancer cell adaptation to chemotherapy. Meanwhile, reduced expression of some miRNAs is correlated with up-regulation of MDR proteins. These miRNAs usually control the expression of MDR-related proteins; thus, chemoresistance may result from down-regulation of these miRNAs. For example, miR-298 directly targets MDR-1 in a dose-dependent manner, resulting in decreased levels of P-gp. Moreover, overexpression of miR-298 reverses chemoresistance in breast cancer cells45. It is notable that miR-27a activates MDR-1 indirectly in ovarian cancer, whereas MDR-1 can be directly targeted by miR-27a in leukemia46,47. The fact that miRNA has dual roles in regulating the same target is reinforced by these findings, and more details will emerge in the future that explain how miRNAs respond to different signaling processes in various tumors. The miRNAs that are reported to regulate MDR-1 are listed (Table 1). Identification of their function highlights a new approach for the development of gene therapy.

Other ABC family members such as MRP1 and BCRP also appear to be targets of miRNAs. MiR-326 was reported to modulate expression of MRP1 in VP-16 resistant cell lines, and induction of miR-326 reversed the resistance of VP-16 as well as doxorubicin60. BCRP is another drug resistance-related protein, which determines the pharmacokinetic properties of drugs in breast cancer cell lines. MiR-328 was found to target BCRP 3′-UTR and influence drug disposition accordingly in human breast cancer cells61. Because the MDR mechanism accounts for only some aspects of drug resistance, more experiments will be needed to explore the actual function of miRNAs in different types of malignancies. Nevertheless, the study of miRNA targeting drug resistance-related proteins will undoubtedly shed light on the therapeutic value of miRNAs.


MicroRNAs alter drug targets

MicroRNAs not only act in a cell-specific manner but also influence drug resistance in a drug-specific way. For example, elevated expression of miR-34a is associated with docetaxel resistance in breast cancer cell lines, while miR-34a conversely sensitizes Ewing's sarcoma cells to doxorubicin and vincristine43,62. Recent development of targeted therapies provides hope that successful cancer treatments are forthcoming. MiRNAs have been found to interfere with specific molecular targets blocked by medications. In non-small cell lung cancer cells, miR-126 efficiently binds to the 3′-UTR of vascular endothelial growth factor A (VEGFA), which is the target of the angiogenesis inhibitor bevacizumab. Furthermore, restoration of miR-126 enhances the sensitivity of tumor cells to anticancer agents, which implies the possibility of combined targeted therapy63. Mutated epidermal growth factor receptor (EGFR/HER1), a cell-surface receptor, is associated with a number of cancers. Therefore, it serves as an important target for anticancer drug therapy. Tyrosine-kinase inhibitors (eg, gefitinib, erlotinib) and monoclonal antibodies (eg, cetuximab, panitumumab) have been developed to inhibit EGFR signaling and approved to treat patients harboring EGFR mutations. It is notable that EGFR pathways crosstalk with some miRNAs during carcinogenesis and drug treatment. For example, EGFR mutations positively regulate miR-21, which in turn increases expression of EGFR64,65. Such a positive feedback loop is critical in maintaining physical homeostasis, but could also be the cause of drug resistance in EGFR inhibitor-treated patients. Similarly, miR-145 inhibits cancer cell growth by targeting EGFR, whereas EGFR suppresses miR-145 to promote tumorigenesis in animal models66,67. These findings reveal one aspect of the buffering role of miRNA that is subject to regulation by its own targets to maintain a balance between positive and negative signaling.

In addition, miRNAs can inactivate drugs by up-regulating downstream effectors of the same pathway. One cause of therapeutic resistance is inactivation of tumor suppressor PTEN, which allows over-activation of the PTEN/PI3K/AKT pathway. Numerous miRNAs target PTEN and function as oncomirs, including miR-17, miR-21, miR-144, and miR-21439,68,69,70. Another example of bypassing growth inhibition is the recruitment of insulin-like growth factor-1 receptor (IGF1), which was found in tumors that overexpressed miR-17-9271. Down-regulation of miRNAs targeting IGF1 leads to tumorigenesis, and restoration of the miRNAs causes growth inhibition of the tumor cells 72. Future studies should address the predictive value of miRNA expression in personalized medicine. Overcoming drug resistance by using miRNAs that share the same targets as anticancer agents may also prove promising73.


MicroRNAs change drug concentrations

The development of chemoresistance is marked by the loss of the drug transport system in cells that results in a decline in the drug concentration inside cells. Gap junction intercellular communications (GJIC) are broadly involved in the transportation of small molecules and second messengers. Gap junction constituents, such as transmembrane protein connexins (Cx), are often lost in cancer cells. Restoration of GJIC suppresses tumor progression and enhances drug sensitivity. The main antitumor function of GJIC relies on the bystander effect (BE), when cytotoxic molecules are transferred from target cells to neighboring cells through GJIC, exposing more cells to chemotherapeutic agents74. MiR-1 and miR-206 have been shown to target connexins, which may lead to impaired GJIC75,76. Another study showed that RNA-binding protein Dnd1 counteracts the function of miR-1 and miR-206 by prohibiting them from associating with their targets77. These results verify that endogenous miRNAs are under the regulation of an intrinsic network. Consequently, systematic down-regulation of miRNAs also drives the development of drug resistance. It was reported that systemic RNA interference-defective-1 transmembrane family member 1 (SIDT1) facilitates intercellular transfer of miR-21, which promotes resistance to gemcitabine in human adenocarcinoma cells78.

In addition to influencing the bystander effect, miRNAs have an impact on cell receptors. The estrogen receptor (ER), which serves as the target of endocrine therapeutic agents such as tamoxifen and raloxifen, is regulated by let-7, miR-206, and miR-221 in breast cancer79,80,81. Interestingly, miR-206 and miR-221 are believed to be responsible for tamoxifen insensitivity, while induction of tamoxifen sensitivity by let-7 could be due to a different binding region. Accumulating evidence suggests that 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] inhibits growth of many types of cancerous cells such as breast cancer and colon cancer. It was shown that miR-125b recognizes the 3′-UTR of the vitamin D receptor and abolishes its expression, resulting in a decrease in the anticancer effects of 1,25(OH)2D382.

In addition to changing drug concentrations at the cellular level, miRNAs influence the pharmacokinetics of drugs in the whole body. For example, cytochrome P450 (CYP), a superfamily of drug-metabolizing enzymes, can be targeted by miR-27b83. In breast cancer tissues, decreased miR-27b is accompanied by a high level of CYP1B1 protein responsible for docetaxel resistance in cancerous cells83,84. Accumulating evidence suggests that miRNAs may exert profound physiological effects on the regulation of the CYP family. For example, CYP1A1 was reported to be targeted by miR-892a, and CYP2J2 is inhibited by let-7b85,86. Recent data indicated that miRNAs repress CYP in a dose-dependent manner. In transgenic mice, knockdown of CYP3A by miRNA-based shRNA dramatically reduces enzymatic activity87. It is known that the liver plays a crucial role in catalyzing drugs. We found that miR-17 impairs nonalcoholic hepatic steatosis in transgenic mice by targeting PPAR-alpha, leading to damaged liver function [Liu et al, Unpublished data].


MicroRNAs influence therapeutic-induced cell death

Various anticancer drugs function by inducing intrinsic and extrinsic apoptosis in tumor cells88. The cellular response to apoptotic signaling can determine the outcome of treatment. There are two principal pathways leading to apoptosis: the mitochondrial intrinsic pathway and the transmembrane extrinsic pathway. The former pathway is mainly under the control of the Bcl-2 family, which includes more than 30 apoptotic regulating molecules89. A number of miRNAs participate in cell apoptosis via interaction with Bcl-2 family members. For example, miR-15/16, miR-21 and miR-125b were all shown to regulate Bcl-2 protein, an anti-apoptotic factor. It was discovered that miR-15/16 induces apoptosis by targeting Bcl-2, whereas suppression of miR-15/16 promotes up-regulation of Bcl-2 and resistance to tamoxifen in breast tumors90. Although miR-21 can bind to the 3′-UTR of Bcl-2 mRNA, it ultimately has an anti-apoptotic role in most tumors91. The reason for this might be that miR-21 has another target, the critical pro-apoptotic molecule Bax, in the same pathway. Down-regulation of Bax by miR-21 inhibits drug-induced apoptosis92. These results highlight another aspect of the buffering role of miRNAs, which interact with the whole signaling pathway by simultaneously controlling both upstream and downstream effectors. Another example is miR-125b, which targets both anti-apoptotic Bcl-2 and pro-apoptotic Bak1, conferring drug resistance and anti-resistance properties in different cancers93,94, which is consistent with our finding that miRNAs play different roles based on spatial and temporal contexts39 (Figure 2).

At the onset of apoptosis, multimeric pro-apoptotic proteins assemble into the apoptosome, which mediates the activation of the caspase reaction. The formation of the apoptosome is often inactivated in tumor cells89. Apaf-1 is an adaptor molecule that forms the backbone of the apoptosome. It was recently revealed that miR-155 negatively regulates Apaf-1 in lung cancer tissue and inhibits the sensitivity of cancer cells to cisplatin95. Other factors may also be involved in apoptosis. Experiments in our lab showed that breast cancer cells transfected with miR-199a-3p have significantly increased sensitivity to docetaxel treatment, as indicated by a prominent increase in sub-G1 apoptotic cells. We then demonstrated that this effect is due to the inhibition of caveolin-2 by miR-199a-3p3. Currently, there are over thirty miRNAs reported to participate in the regulation of cell cycle progression by modulating various pathways, such as RAS, AKT, E2F1, and p536. This research identifies a new type of miRNA-mediated drug resistance in cancer cells.


MicroRNAs regulate angiogenesis

We initially illustrated that endogenously expressed miRNAs can play an important role in tumor angiogenesis. In glioblastoma cells, miR-378 contributes to cell survival in vitro and tumor growth and vascularization in vivo by targeting SuFu and Fus-196. Aggressive angiogenesis helps tumor cells escape treatment and metastasize to distant organs. Recent studies have shown that a variety of miRNAs (eg, miR-126, miR-130a, miR-210, and miR-296), termed angiomiRs, regulate tumor angiogenesis97. For example, overexpression of miR-93 in U87 cells increases tube formation in vitro and neovascularization in vivo98. While many miRNAs function as pro-angiogenic regulators, some miRNAs can suppress tumor angiogenesis. In breast cancer, endogenous miR-126 inhibits endothelial cell recruitment and angiogenesis that are essential for metastasis by targeting insulin-like growth factor binding protein 2 (IGFBP2)99. In the well-studied miR-17∼92 cluster, miR-92a was also identified as a negative regulator of angiogenesis that acts by down-regulating integrin alpha 5100.

A number of therapeutic approaches (bevacizumab, sorafenib, sunitinib, etc) that block the vascular supply to tumors have reached the clinic. However, only a fraction of patients benefit from treatment because tumors develop resistance to vascular endothelial growth factor (VEGF) inhibitors101. Computational analysis predicted that at least 96 miRNAs are directly involved in VEGF regulation102. These miRNAs were shown to be associated with the efficacy of anti-VEGF treatment103. Apart from binding the 3′-UTR of VEGF mRNA, many miRNAs can mediate VEGF signaling pathway indirectly. It was demonstrated that aberrant regulation of von Hippel-Lindau tumor suppressor(VHL) induces hypoxia inducible factor-1(HIF-1) alpha activation, which promotes autocrine VEGF secretion in leukemia104. Over-activation of tumor-derived VEGF might be responsible for treatment failure. In glioblastoma cells, miR-17 was responsible for the activation of VEGF by activating the upstream factor HIF-1 alpha. Interestingly, these effects become dramatically significant when the tumor cells are starved or exposed to chemotherapy39. These findings favor the application of anti-angiogenesis therapy combined with chemotherapeutic agents. It is currently unclear how anti-VEGF therapy alone influences tumor growth. Further investigation of the involvement of miRNAs with tumor angiogenesis might provide more clues for optimizing the selection of anti-angiogenesis treatments.


MicroRNAs in the generation of tumor stem cells

Tumor stem cells (TSCs) have long been considered a cause of cancer recurrence during the treatment of cancer. TSCs are thought to be responsible for therapeutic resistance, tumor metastasis and relapse. Since being discovered in acute myeloid leukemia cells in 2003, TSCs have been reported in most tumor types105. In recent years, the relationship between miRNAs and TSCs has been confirmed with the identification of several miRNAs that control key biological properties of TSCs in breast cancer, prostate cancer and glioblastoma106. Song's group was the first to examine the relationship between miRNAs and breast cancer stem cells107. They analyzed the expression of let-7 in breast tumor-initiating cells and found that let-7 was dramatically reduced in TSCs. They then identified let-7 as a key regulator of tumor stem cell characteristics through silencing of H-RAS and HMGA2107. Though methods to identify stem cells in cancer are controversial, CD44 and CD133 have been widely used as surface markers of TSCs107. Interestingly, a recent study suggested that miR-34a inhibits TSCs formation in prostate cancer by directly repressing CD44108, indicating that miRNAs might take part in the regulation of TSCs. In addition, some miRNAs possess the ability to promote the generation of TSCs by down-regulating tumor suppressors. In hepatocellular carcinoma, miR-130b is associated with TSC growth that leads to worse overall survival and more frequent recurrence of cancer in patients. The increased miR-130b occurs in parallel with the reduction of tumor protein 53-induced nuclear protein 1, a known miR-130b target. Furthermore, cells transfected with miR-130b have a higher resistance to chemotherapeutic agents109.

Tumor stem cells are believed to be capable of self-renewal and give rise to tumorigenesis. In glioblastoma cells, we found that cells transfected with miR-378 contain a large group of side population (SP) cells that have a high density of TSCs110. Overexpression of miR-378 enhances colony formation and cell survival, which is due to the up-regulation of stem cell marker Sox-2110,111. Interestingly, cells harboring higher percentages of TSCs grow more slowly under normal conditions, but display significant survival advantages when stressed by treatment with anticancer agents39. Therefore, it is likely that miRNAs control the development of TSCs at multiple levels.


Conclusion and perspective

Are miRNAs friends or foes in cancer treatment? This question might be too broad to answer concisely. As discussed above, the effect of miRNAs in drug resistance might be positive or negative, or might even vary under different circumstances (Figure 3). Taking evolutionary conservation into consideration, the nature of miRNAs in physiological conditions could be more similar to buffering. Emerging data suggest that miRNAs are important for balancing different signaling processes and helping to maintain homeostasis112. It has been well established that cancer is a heterogeneous group of diseases. Thus, personalized medicine has evolved as a future direction in clinical oncology. Down-regulation of miRNA networks has been shown to be the root of cancer development. Therefore, therapeutic strategies should focus on rebalancing miRNA networks. Meanwhile, miRNA profiling will have promising diagnostic and prognostic value.


The authors thank Mr Shaan Gupta for preparation of the article. Our studies were supported by grants from the Canadian Institutes of Health Research (MOP-102635, MOP-111171) and the Natural Sciences and Engineering Research Council of Canada (NSERC, 227937-2012) to BBY, who is the recipient of a Career Investigator Award (CI 7418) from the Heart and Stroke Foundation of Ontario. HL is a recipient of the Connaught International Student Award.


References
Gong J,Jaiswal R,Mathys JM,Combes V,Grau GE,Bebawy M. Microparticles and their emerging role in cancer multidrug resistanceCancer Treat RevYear: 2012382263421757296
Viticchie G,Lena AM,Latina A,Formosa A,Gregersen LH,Lund AH,et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell linesCell CycleYear: 20111011213121368580
Shatseva T,Lee DY,Deng Z,Yang BB. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2J Cell SciYear: 201112428263621807947
Yu B,Zhou S,Wang Y,Qian T,Ding G,Ding F,et al. miR-221 and miR-222 promote Schwann cell proliferation and migration by targeting LASS2 after sciatic nerve injuryJ Cell SciYear: 201212526758322393241
Pernaute B,Spruce T,Rodriguez TA,Manzanares M. MiRNA-mediated regulation of cell signaling and homeostasis in the early mouse embryoCell CycleYear: 2011105849121293181
Liang LH,He XH. Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapyActa Pharmacol SinYear: 20113213112021909123
Lerner M,Lundgren J,Akhoondi S,Jahn A,Ng HF,Akbari Moqadam F,et al. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progressionCell CycleYear: 20111021728321597324
Du WW,Yang BB,Yang BL,Deng Z,Fang L,Shan SW,et al. Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapyPLoS OneYear: 20116e2639622096483
Fang L,Du WW,Yang W,Rutnam ZJ,Peng C,Li H,et al. MiR–93 enhances angiogenesis and metastasis by targeting LATS2Cell CycleYear: 20121143526523111389
Luo L,Ye G,Nadeem L,Fu G,Yang BB,Honarparvar E,et al. MicroRNA-378a-5p promotes trophoblast cell survival, migration and invasion by targeting NodalJ Cell SciYear: 201212531243222454525
Siragam V,Rutnam ZJ,Yang W,Fang L,Luo L,Yang X,et al. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11OncotargetYear: 2012313708523211491
Du WW,Fang L,Li M,Yang X,Liang Y,Peng C,et al. MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signalingJ Cell SciYear: 2013doi:10.1242/jcs.118299
Rutnam ZJ,Yang BB. The non-coding 3′ UTR of CD44 induces metastasis by regulating extracellular matrix functionsJ Cell SciYear: 201212520758522637644
Kahai S,Lee SC,Lee DY,Yang J,Li M,Wang CH,et al. MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7PLoS OneYear: 20094e753519844573
Wang CH,Lee DY,Deng Z,Jeyapalan Z,Lee SC,Kahai S,et al. MicroRNA miR-328 regulates zonation morphogenesis by targeting CD44 expressionPLoS OneYear: 20083e242018560585
Lee DY,Shatseva T,Jeyapalan Z,Du WW,Deng Z,Yang BB. A 3′-untranslated region (3′UTR) induces organ adhesion by regulating miR-199a* functionsPLoS OneYear: 20094e452719223980
Lee DY,Jeyapalan Z,Fang L,Yang J,Zhang Y,Yee AY,et al. Expression of versican 3′-untranslated region modulates endogenous microRNA functionsPLoS OneYear: 20105e1359921049042
Jeyapalan Z,Deng Z,Shatseva T,Fang L,He C,Yang BB. Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesisNucleic Acids ResYear: 20113930264121149267
Lee SC,Fang L,Wang CH,Kahai S,Deng Z,Yang BB. A non-coding transcript of nephronectin promotes osteoblast differentiation by modulating microRNA functionsFEBS LettYear: 20115852610621784074
Fang L,Du WW,Yang X,Chen K,Ghanekar A,Levy G,et al. Versican 3′-untranslated region (3′-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activityFASEB JYear: 2013279071923180826
Poliseno L,Salmena L,Zhang J,Carver B,Haveman WJ,Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biologyNatureYear: 20104651033820577206
Cesana M,Cacchiarelli D,Legnini I,Santini T,Sthandier O,Chinappi M,et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNACellYear: 20111473586922000014
Rutnam ZJ,Wight TN,Yang BB. miRNAs regulate expression and function of extracellular matrix moleculesMatrix BiolYear: 201232748523159731
Shan SW,Lee DY,Deng Z,Shatseva T,Jeyapalan Z,Du WW,et al. MicroRNA MiR-17 retards tissue growth and represses fibronectin expressionNat Cell BiolYear: 2009111031819633662
Vasudevan S,Tong Y,Steitz JA. Switching from repression to activation: microRNAs can up-regulate translationScienceYear: 20073181931418048652
Yang X,Rutnam ZJ,Jiao C,Wei D,Xie Y,Du J,et al. An anti-let-7 sponge decoys and decays endogenous let-7 functionsCell CycleYear: 201211309710822871741
Li BA. A novel tumor suppressor miRNA miR-520e contributes to suppression of hepatomaActa Pharmacol SinYear: 2012333422212428
Jiang Q,Wang Y,Hao Y,Juan L,Teng M,Zhang X,et al. miR2Disease: a manually curated database for microRNA deregulation in human diseaseNucleic Acids ResYear: 200937D9810418927107
Sun K,Wang W,Zeng JJ,Wu CT,Lei ST,Li GX. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinomaActa Pharmacol SinYear: 2011323758421278784
Yang S,Li Y. MicroRNAs: novel factors in clinical diagnosis and prognosis for nasopharyngeal carcinomaActa Pharmacol SinYear: 201233981222751478
Ye G,Fu G,Cui S,Zhao S,Bernaudo S,Bai Y,et al. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor–like kinase 7: implications for chemoresistanceJ Cell SciYear: 20111243596821224400
Rutnam ZJ,Yang BB. The involvement of microRNAs in malignant transformationHistol HistopatholYear: 20122712637022936445
Fang L,Du WW,Yang W,Rutnam ZJ,Peng C,Li H,et al. MiR-93 enhances angiogenesis and metastasis by targeting LATS2Cell CycleYear: 20121143526523111389
Siragam V,Rutnam ZJ,Yang W,Fang L,Luo L,Yang X,et al. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11OncotargetYear: 2012313708523211491
Wang D,Qiu C,Zhang H,Wang J,Cui Q,Yin Y. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targetsPLoS OneYear: 20105e1306720927335
He L,Thomson JM,Hemann MT,Hernando-Monge E,Mu D,Goodson S,et al. A microRNA polycistron as a potential human oncogeneNatureYear: 20054358283315944707
Hossain A,Kuo MT,Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNAMol Cell BiolYear: 200626819120116940181
Mateescu B,Batista L,Cardon M,Gruosso T,de Feraudy Y,Mariani O,et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress responseNat MedYear: 20111716273522101765
Li H,Yang BB. Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2OncotargetYear: 2012316536823391506
Shan SW,Fang L,Shatseva T,Rutnam ZJ,Yang X,Lu WY,et al. Mature MiR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7, and vimentin in different signal pathwaysJ Cell SciYear: 2013doi:10.1242/jcs.122895
Baguley BC. Multiple drug resistance mechanisms in cancerMol BiotechnolYear: 2010463081620717753
Liang Z,Li Y,Huang K,Wagar N,Shim H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTENPharm ResYear: 201128309110021853360
Kastl L,Brown I,Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cellsBreast Cancer Res TreatYear: 20121314455421399894
Shi GH,Ye DW,Yao XD,Zhang SL,Dai B,Zhang HL,et al. Involvement of microRNA-21 in mediating chemoresistance to docetaxel in androgen-independent prostate cancer PC3 cellsActa Pharmacol SinYear: 2010318677320581857
Bao L,Hazari S,Mehra S,Kaushal D,Moroz K,Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298Am J PatholYear: 2012180249050322521303
Zhu H,Wu H,Liu X,Evans BR,Medina DJ,Liu CG,et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cellsBiochem PharmacolYear: 200876582818619946
Feng DD,Zhang H,Zhang P,Zheng YS,Zhang XJ,Han BW,et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemiaJ Cell Mol MedYear: 20111521647521070600
Bourguignon LY,Spevak CC,Wong G,Xia W,Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cellsJ Biol ChemYear: 2009284265334619633292
Zhu X,Li Y,Shen H,Li H,Long L,Hui L,et al. miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1Acta Biochim Biophys Sin (Shanghai)Year: 20134580623178914
Chen J,Tian W,Cai H,He H,Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancerMed OncolYear: 20122925273422101791
Kovalchuk O,Filkowski J,Meservy J,Ilnytskyy Y,Tryndyak VP,Chekhun VF,et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicinMol Cancer TherYear: 200872152918645025
Asuthkar S,Velpula KK,Chetty C,Gorantla B,Rao JS. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivityOncotargetYear: 2012314395423183822
Ikemura K,Yamamoto M,Miyazaki S,Mizutani H,Iwamoto T,Okuda M. Microrna-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cellsMol PharmacolYear: 20138339940523166305
Boyerinas B,Park SM,Murmann AE,Gwin K,Montag AG,Zillhardt M,et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1Int J CancerYear: 201213017879721618519
Li Z,Hu S,Wang J,Cai J,Xiao L,Yu L,et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cellsGynecol OncolYear: 20101191253020624637
Yang L,Li N,Wang H,Jia X,Wang X,Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistanceOncol RepYear: 20122859260022614869
Xu Y,Xia F,Ma L,Shan J,Shen J,Yang Z,et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrestCancer LettYear: 2011310160921802841
Zhao X,Yang L,Hu J,Ruan J. miR-138 might reverse multidrug resistance of leukemia cellsLeuk ResYear: 20103410788219896708
Fujita Y,Kojima K,Ohhashi R,Hamada N,Nozawa Y,Kitamoto A,et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expressionJ Biol ChemYear: 2010285190768420406806
Liang Z,Wu H,Xia J,Li Y,Zhang Y,Huang K,et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1Biochem PharmacolYear: 2010798172419883630
Pan YZ,Morris ME,Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cellsMol PharmacolYear: 2009751374919270061
Nakatani F,Ferracin M,Manara MC,Ventura S,Del Monaco V,Ferrari S,et al. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemosensitivity and malignancyJ PatholYear: 201222679680521960059
Zhu X,Li H,Long L,Hui L,Chen H,Wang X,et al. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor AActa Biochim Biophys Sin (Shanghai)Year: 2012445192622510476
Seike M,Goto A,Okano T,Bowman ED,Schetter AJ,Horikawa I,et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokersProc Natl Acad Sci U S AYear: 2009106120859019597153
Zhou X,Ren Y,Moore L,Mei M,You Y,Xu P,et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN statusLab InvestYear: 2010901445520048743
Cho WC,Chow AS,Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1RNA BiolYear: 201181253121289483
Zhu H,Dougherty U,Robinson V,Mustafi R,Pekow J,Kupfer S,et al. EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulatorsMol Cancer ResYear: 201199607521653642
Darido C,Georgy SR,Wilanowski T,Dworkin S,Auden A,Zhao Q,et al. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesisCancer CellYear: 2011206354822094257
Zhang LY,Ho–Fun Lee V,Wong AM,Kwong DL,Zhu YH,Dong SS,et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTENCarcinogenesisYear: 2013344546323125220
Wang YS,Wang YH,Xia HP,Zhou SW,Schmid-Bindert G,Zhou CC. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell linesAsian Pac J Cancer PrevYear: 2012132556022502680
Ernst A,Campos B,Meier J,Devens F,Liesenberg F,Wolter M,et al. De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid culturesOncogeneYear: 20102934112220305691
McKinsey EL,Parrish JK,Irwin AE,Niemeyer BF,Kern HB,Birks DK,et al. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAsOncogeneYear: 20113049102021643012
Rai K,Takigawa N,Ito S,Kashihara H,Ichihara E,Yasuda T,et al. Liposomal delivery of microRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor–resistance in lung cancer cellsMol Cancer TherYear: 2011101720721712475
Kandouz M,Batist G. Gap junctions and connexins as therapeutic targets in cancerExpert Opin Ther TargetsYear: 2010146819220446866
Yang B,Lin H,Xiao J,Lu Y,Luo X,Li B,et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2Nat MedYear: 2007134869117401374
Anderson C,Catoe H,Werner R. MIR-206 regulates connexin43 expression during skeletal muscle developmentNucleic Acids ResYear: 20063458637117062625
Kedde M,Strasser MJ,Boldajipour B,Oude Vrielink JA,Slanchev K,le Sage C,et al. RNA-binding protein Dnd1 inhibits microRNA access to target mRNACellYear: 200713112738618155131
Elhassan MO,Christie J,Duxbury MS. Homo sapiens systemic RNA interference-defective-1 transmembrane family member 1 (SIDT1) protein mediates contact-dependent small RNA transfer and microRNA-21-driven chemoresistanceJ Biol ChemYear: 201228752677722174421
Zhao Y,Deng C,Lu W,Xiao J,Ma D,Guo M,et al. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancerMol MedYear: 20111712334121826373
Adams BD,Furneaux H,White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell linesMol EndocrinolYear: 20072111324717312270
Zhao JJ,Lin J,Yang H,Kong W,He L,Ma X,et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancerJ Biol ChemYear: 2008283310798618790736
Mohri T,Nakajima M,Takagi S,Komagata S,Yokoi T. MicroRNA regulates human vitamin D receptorInt J CancerYear: 200912513283319437538
Tsuchiya Y,Nakajima M,Takagi S,Taniya T,Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1Cancer ResYear: 2006669090816982751
Martinez VG,O'Connor R,Liang Y,Clynes M. CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistanceBr J CancerYear: 2008985647018212750
Choi YM,An S,Lee EM,Kim K,Choi SJ,Kim JS,et al. CYP1A1 is a target of miR-892a-mediated post-transcriptional repressionInt J OncolYear: 201241331622470100
Chen F,Chen C,Yang S,Gong W,Wang Y,Cianflone K,et al. Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2PLoS OneYear: 20127e3919722761738
Wang Y,Hu HH,Pang H,Zhou XY,Yu LS,Wang LL,et al. Lentiviral transgenic microRNA-based shRNA suppressed mouse cytochromosome P450 3A (CYP3A) expression in a dose-dependent and inheritable mannerPLoS OneYear: 20127e3056022291988
Zhang Y,Yang JM. The impact of cellular senescence in cancer therapy: is it true or notActa Pharmacol SinYear: 201132119920721909124
Pommier Y,Sordet O,Antony S,Hayward RL,Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networksOncogeneYear: 20042329344915077155
Cittelly DM,Das PM,Salvo VA,Fonseca JP,Burow ME,Jones FE. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumorsCarcinogenesisYear: 20103120495720876285
Dong J,Zhao YP,Zhou L,Zhang TP,Chen G. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cellsArch Med ResYear: 20114281421376256
Shi L,Chen J,Yang J,Pan T,Zhang S,Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase–3 activityBrain ResYear: 201013522556420633539
Zhou M,Liu Z,Zhao Y,Ding Y,Liu H,Xi Y,et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expressionJ Biol ChemYear: 20102852149650720460378
Zhao A,Zeng Q,Xie X,Zhou J,Yue W,Li Y,et al. MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expressionJ Genet GenomicsYear: 201239293522293115
Zang YS,Zhong YF,Fang Z,Li B,An J. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf–1 expressionCancer Gene TherYear: 201219773822996741
Lee DY,Deng Z,Wang CH,Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expressionProc Natl Acad Sci U S AYear: 200710420350518077375
Weis SM,Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targetsNat MedYear: 20111713597022064426
Fang L,Deng Z,Shatseva T,Yang J,Peng C,Du WW,et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8OncogeneYear: 2011308062120956944
Png KJ,Halberg N,Yoshida M,Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cellsNatureYear: 2012481190422170610
Bonauer A,Carmona G,Iwasaki M,Mione M,Koyanagi M,Fischer A,et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in miceScienceYear: 20093241710319460962
Potente M,Gerhardt H,Carmeliet P. Basic and therapeutic aspects of angiogenesisCellYear: 20111468738721925313
Hua Z,Lv Q,Ye W,Wong CK,Cai G,Gu D,et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxiaPLoS OneYear: 20061e11617205120
Mekenkamp LJ,Tol J,Dijkstra JR,de Krijger I,Vink-Borger ME,van Vliet S,et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patientsBMC CancerYear: 20121229222804917
Ghosh AK,Shanafelt TD,Cimmino A,Taccioli C,Volinia S,Liu CG,et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cellsBloodYear: 200911355687419336759
Visvader JE,Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questionsNat Rev CancerYear: 200887556818784658
Liu C,Tang DG. MicroRNA regulation of cancer stem cellsCancer ResYear: 2011715950421917736
Yu F,Yao H,Zhu P,Zhang X,Pan Q,Gong C,et al. let-7 regulates self renewal and tumorigenicity of breast cancer cellsCellYear: 200713111092318083101
Liu C,Kelnar K,Liu B,Chen X,Calhoun-Davis T,Li H,et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44Nat MedYear: 201117211521240262
Ma S,Tang KH,Chan YP,Lee TK,Kwan PS,Castilho A,et al. miR-130b promotes CD133+ liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1Cell Stem CellYear: 2010769470721112564
Deng Z,Yang X,Fang L,Rutnam ZJ,Yang BB. Misprocessing and functional arrest of microRNAs by miR-Pirate: roles of miR-378 and miR-17Biochem JYear: 20134503758623210454
Wu QP,Xie YZ,Deng Z,Li XM,Yang W,Jiao CW,et al. Ergosterol peroxide isolated from Ganoderma lucidum abolishes microRNA miR-378-mediated tumor cells on chemoresistancePLoS OneYear: 20127e4457922952996
Mendell JT,Olson EN. MicroRNAs in stress signaling and human diseaseCellYear: 201214811728722424228

Article Categories:
  • Review

Keywords: cancer, chemotherapy, miRNA, stem cell, miR-17, stress response, drug resistance.

Previous Document:  Positive allosteric modulators to peptide GPCRs: a promising class of drugs.
Next Document:  Effect of myocardial contractility on hemodynamic end points under concomitant microvascular disease...